Cannabis use disorder (CUD) and major depressive disorder (major depression) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively. Both disorders are characterized by anhedonia, diminished motivation, and blunted neural reward sensitivity.
Official registry: https://clinicaltrials.gov/study/NCT07924852 · Florida State University · enrollment listed as 54
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Transcranial Alternating Current Stimulation Sham, Transcranial Alternating Current Delta Stimulation., or Transcranial Alternating Current Theta Stimulation. The registry lists allocation as randomized. Cannabis use disorder (CUD) and major depressive disorder (major depression) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively.
They plan to enroll about 54 people at 2 sites. Taking part typically means using or being fitted with a device plus check-ins.
Delta and Theta-Frequency Transcranial Alternating Stimulation Neuromodulation of Motivation and Reward Oscillations in Disorder of Reward Dysfunction.
Interventions: Transcranial Alternating Current Stimulation Sham, Transcranial Alternating Current Delta Stimulation., Transcranial Alternating Current Theta Stimulation
Primary outcome (registry wording): Effort-updating behavior during decision period.
Zoe Howell Doctoral Student PI, M.Res.
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).
NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
Background: There are no good treatments for people considering suicide. Researchers want to study suicide with questions, blood tests, brain imaging, and sleep studies.
NCT02543983 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
NCT02649985 · Official ClinicalTrials.gov record · Brigham and Women's Hospital
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary